Down-regulation of lipoprotein lipase increases glucose uptake in L6 muscle cells

Biochemical and Biophysical Research Communications

Volumn 389, Issue 1, 2009, Pages 34-39

  Lopez, Veronica ^a   Saraff, Kumuda ^a   Medh, Jheem D ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Ciglitazone; Glucose uptake; Lipoprotein lipase; PPAR ; Rat L6 cells; siRNA; Skeletal muscle

Indexed keywords

CIGLITAZONE; GLITAZONE DERIVATIVE; GLUCOSE TRANSPORTER 4; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL INTERFERING RNA; TROGLITAZONE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; MUSCLE CELL; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE;

ANIMALS; CELL LINE; DOWN-REGULATION; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPOPROTEIN LIPASE; MUSCLE CELLS; MUSCLE, SKELETAL; PPAR GAMMA; RATS; RNA, SMALL INTERFERING; THIAZOLIDINEDIONES;

RATTUS;

EID: 70349292061     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.08.081     Document Type: Article

References (18)

1. Rangwala S.M., and Lazar M.A. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol. Sci. 25 (2004) 331-336
2. Wilson T.M., and Wahli W. Peroxisome proliferator-activated receptor agonists. Curr. Opin. Chem. Biol. 1 (1997) 235-241
3. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferators-activated receptor γ agonists. J. Clin. Invest. 106 (2000) 467-472
4. Kumar S., Boulton A.J.M., Beck-Nielsen H., Berthezene F., Muggeo M., Persson B., Spinas G.A., Donoghue S., Lettis S., and Stewart-Long P. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients, Troglitazone Study Group. Diabetologia 39 (1996) 701-709
5. Hsueh W.A., and Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am. J. Cardiol. 92 (2003) 3J-9J
6. Kintscher U., and Law R.E. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E287-E291
7. Hevener A.L., He W., Barak Y., Le J., Bandyopadhyay G., Olson P., Wilkes J., Evans R.M., and Olefsky J. Muscle-specific PPAR γ deletion causes insulin resistance. Nat. Med. 9 (2003) 1491-1497
8. Eckel R.H. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N. Engl. J. Med. 320 (1989) 1060-1068
9. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., Staels B., and Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15 (1996) 5336-5348
10. Ferreira L.D.M.C.-B., Pulawa L.K., Jensen D.R., and Eckel R.H. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes 50 (2001) 1064-1068
11. - Δ Δ CT method. Methods 25 (2001) 402-408
12. Walczak R., and Tontonoz P. PPRadigms and PPARadoxes: expanding roles for PPAR-gamma in the control of lipid metabolism. J. Lipid Res. 43 (2002) 177-186
13. Norris A.W., Chen L., Fisher S.J., Szanto I., Ristow M., Jozsi A.C., Hirshman M.F., Rosen E.D., Goodyear L.J., Gonzalez F.J., Spiegelman B.M., and Kahn C.R. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112 (2003) 608-618
14. Ciaraldi T.P., Gilmore A., Olefsky J.M., Goldberg M., and Heidenreich K.A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39 (1990) 1056-1062
15. Yonemitsu S., Nishimura H., Shintani M., Inoue R., Yamamoto Y., Masuzaki H., Ogawa Y., Hosoda K., Inoue G., Hayashi T., and Nakao K. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50 (2001) 1093-1101
16. Pulawa L.K., and Eckel R.H. Overexpression of muscle lipoprotein lipase and insulin sensitivity. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002) 569-574
17. Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., Lutz E.P., Kako Y., Velz-Carrasco W., Goldbeg I.J., Breslow J.L., and Shulman G.I. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. USA 98 (2001) 7522-7577
18. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007) 2457-2471